Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M890Revenue $M14.2Net Margin (%)-787.6Z-Score8.7
Enterprise Value $M667EPS $-3.3Operating Margin %-635.0F-Score4
P/E(ttm))0Cash Flow Per Share $0Pre-tax Margin (%)-787.6Higher ROA y-yY
Price/Book3.710-y EBITDA Growth Rate %-9.1Quick Ratio6.6Cash flow > EarningsY
Price/Sales48.15-y EBITDA Growth Rate %25.2Current Ratio6.6Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-38.4Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-45.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M40.7ROI % (ttm)-300.9Gross Margin Increase y-yN

Gurus Latest Trades with SRPT

Number of guru portfolios checked: 56.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SRPTGeorge Soros 2014-03-31 Reduce-0.04%$17.91 - $30.29
($25.36)
$ 21.88-14%Reduce -89.27%25,000
SRPTGeorge Soros 2013-12-31 Reduce-0.22%$12.89 - $53.81
($29.58)
$ 21.88-26%Reduce -64.98%233,000
SRPTGeorge Soros 2013-09-30 Add0.12%$30.906 - $47.97
($38.37)
$ 21.88-43%Add 56.28%665,274
SRPTGeorge Soros 2013-03-31 Add0.08%$23.97 - $36.95
($28.83)
$ 21.88-24%Add 82.54%413,329
SRPTGeorge Soros 2012-12-31 Add0.05%$14.99 - $44.93
($26.74)
$ 21.88-18%Add 184.13%226,429
SRPTJean-Marie Eveillard 2012-03-31 Sold Out $4.5 - $9.6
($6.06)
$ 21.88261%Sold Out0
SRPTJean-Marie Eveillard 2011-12-31 Reduce$3.24 - $6.54
($5.04)
$ 21.88334%Reduce -83.33%50,000
SRPTJean-Marie Eveillard 2011-09-30 Add$6.3 - $9.9
($7.92)
$ 21.88176%Add 50%300,000
SRPTJean-Marie Eveillard 2011-06-30 Buy $8.1 - $11.22
($9.66)
$ 21.88126%New holding, 200000 sh.200,000
SRPTGeorge Soros 2006-03-31 Buy 0.08%$24.54 - $50.45
($41.39)
$ 21.88-47%New holding, 308100 sh.308,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SRPT is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
SRPT George Soros 2014-03-3125,0000.060.01-89.27%
Premium Most recent portfolio changes are included for Premium Members only!


SRPT: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CHASE ANTHONY RDirector 2013-11-14Buy10,000$13.9554.62view
Aphale JayantSVP Technical Operations 2013-11-12Sell15,933$12.5671.74view
BEHRENS M KATHLEENDirector 2013-09-16Buy6,500$37.04-41.77view
HODGMAN JOHNDirector 2013-09-03Sell5,556$34.97-38.32view
CHASE ANTHONY RDirector 2013-08-22Buy3,500$32.68-34view
Mahatme SandeshSenior Vice President, CFO 2013-08-20Buy5,000$31.1-30.64view
Price Ben GilDirector 2013-08-19Buy500$31.18-30.82view
CHASE ANTHONY RDirector 2013-06-14Buy10,000$38.5-43.97view
CHASE ANTHONY RDirector 2012-11-28Sell10,000$29.46-26.78view
CHASE ANTHONY RDirector 2012-11-14Sell10,000$25.7-16.07view

Press Releases about SRPT :

    Quarterly/Annual Reports about SRPT:

    News about SRPT:

    Articles On GuruFocus.com
    Insiders Are Buying Fate Therapeutics Oct 09 2013 
    comment on SRPT Mar 16 2013 
    comment on SRPT Mar 16 2013 
    comment on SRPT Feb 16 2013 


    More From Other Websites
    Nasdaq stocks posting largest percentage decreases Jul 21 2014
    Your first trade for Friday Jul 17 2014
    [video] Fast Money Final Trade: GOOGL, MSFT & more Jul 17 2014
    The Zacks Analyst Blog Highlights: AbbVie, Shire, Gilead Sciences, Sarepta Therapeutics and Celgene Jul 17 2014
    Sarepta Plunges on Eteplirsen Study Results Jul 11 2014
    Today's Dead Cat Bounce Stock Is Sarepta Therapeutics (SRPT) Jul 11 2014
    Sarepta Therapeutics Slumps: SRPT Tanks 12.9% in Session Jul 11 2014
    [video] Stock Pops & Drops: COH, SRPT, CRAY, LB Jul 10 2014
    Deutsche Bank Questions Long-Term Efficacy Of Sarepta's Eteplirsen Following Trial News Jul 10 2014
    Investors Remain Confident in Sarepta After Shares Fall 20 Percent Jul 10 2014
    Sarepta price target lowered to $34 from $52 at Roth Capital Jul 10 2014
    Sarepta Therapeutics Reports Long-Term Outcomes Through 144 Weeks from Phase IIb Study of Eteplirsen... Jul 10 2014
    Sarepta potential for near-term approval lower after update, says Piper Jaffray Jul 10 2014
    Janney Capital reiterates Sell rating on Sarepta Jul 10 2014

    Add Notes, Comments or Ask Questions

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK
    Email Hide